hot at the injection site; scheduled 2nd dose 9Apr2021, vaccine provider did not feel comfortable administering vaccine at time due to swollen lymph nodes and other pre-existing medical conditions; fever; swelling in lymph nodes around collar bone; exhausted; rash at injection site; felt terrible; arm on fire-right; Right arm sore at around injection site; migraine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Right arm sore at around injection site), MIGRAINE (migraine), VACCINATION SITE RASH (rash at injection site), LYMPHADENOPATHY (swelling in lymph nodes around collar bone) and ASTHENIA (exhausted) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Tendinitis and Bursitis. Concurrent medical conditions included Penicillin allergy, Type I diabetes mellitus and Asthma. Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) for Allergy, MONTELUKAST SODIUM (SINGULAIR), SERTRALINE HYDROCHLORIDE (ZOLOFT), BUSERELIN ACETATE (BUSERIN), FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR), IPRATROPIUM BROMIDE, SALBUTAMOL (BREVA) and INSULIN ASPART (NOVOLOG) for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced VACCINATION SITE PAIN (Right arm sore at around injection site), MIGRAINE (migraine) and MYALGIA (arm on fire-right). On 29-Mar-2021, the patient experienced VACCINATION SITE RASH (rash at injection site) and FEELING ABNORMAL (felt terrible). On 31-Mar-2021, the patient experienced LYMPHADENOPATHY (swelling in lymph nodes around collar bone) and ASTHENIA (exhausted). On 10-Apr-2021, the patient experienced PYREXIA (fever). On an unknown date, the patient experienced VACCINATION SITE WARMTH (hot at the injection site) and INTENTIONAL PRODUCT USE ISSUE (scheduled 2nd dose 9Apr2021, vaccine provider did not feel comfortable administering vaccine at time due to swollen lymph nodes and other pre-existing medical conditions). The patient was treated with IBUPROFEN (ADVIL 12 HOUR) at an unspecified dose and frequency; PARACETAMOL (TYLENOL) at an unspecified dose and frequency and INSULIN for Hyperglycemia, at an unspecified dose and frequency. On 11-Apr-2021, PYREXIA (fever) had resolved. On 13-Apr-2021, LYMPHADENOPATHY (swelling in lymph nodes around collar bone) had not resolved. At the time of the report, VACCINATION SITE PAIN (Right arm sore at around injection site), MIGRAINE (migraine), VACCINATION SITE RASH (rash at injection site), ASTHENIA (exhausted), VACCINATION SITE WARMTH (hot at the injection site), FEELING ABNORMAL (felt terrible), MYALGIA (arm on fire-right) and INTENTIONAL PRODUCT USE ISSUE (scheduled 2nd dose 9Apr2021, vaccine provider did not feel comfortable administering vaccine at time due to swollen lymph nodes and other pre-existing medical conditions) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Mar-2021, Blood glucose abnormal: (High) blood sugar 320 (lasted 3 days)..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications: typing errors: SINGULAIR instead of cingulair, BUSERIN instead of bucerin, BREVA instead of bereva and trichendin (did not code). Treatment details included : Insulin to reduce glucose levels, Advil, Tylenol. Event outcome of events were not reported.   Most recent FOLLOW-UP information incorporated above includes: On 20-Apr-2021: This follow-up was received on 20-APR-2021.  The patient updated the historical conditions( tendinitis and bursitis). Events updated.